Sucampo Pharmaceuticals Inc

Most Recent

  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    Key Risks Facing Sucampo Pharmaceuticals in 2017

    Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

    By Kenneth Smith
  • uploads///Sucampo pipeline pre
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Research Pipeline in December 2017

    Sucampo Pharmaceuticals (SCMP) recently completed a Phase 3 study for the alternate sprinkle formulation of Amitiza (lubiprostone) in adults with CIC (chronic idiopathic constipation).

    By Kenneth Smith
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    The Financial Performance of Sucampo Pharmaceuticals

    Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.

    By Kenneth Smith
  • uploads///VTS
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape

    In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.

    By Kenneth Smith
  • uploads///Amitiza performance
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Amitiza: Its Performance in 2017

    Sucampo Pharmaceuticals has granted licenses to commercialize a generic or authorized generic of Amitiza in the United States to Par Pharmaceutical and Dr. Reddy’s Laboratories.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.